Biodexa Pharmaceuticals (BDRX) announced the enrolment of the first three patients by the University of Bonn, Germany into its pivotal Phase 3 Serenta trial of eRapa in patients with familial adenomatous polyposis, a mostly inherited disease that, if left untreated, almost always leads to colorectal cancer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDRX:
- Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial
- Biodexa Pharmaceuticals files to sell 3.38M units
- Biodexa Pharmaceuticals’ Phase 3 Serenta Trial Approved in Europe
- Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP
- Biodexa Pharmaceuticals’ Phase 3 Trial Update: A Potential Breakthrough in FAP Treatment